Alexion Is Undervalued And Ripe For Acquisition

At $23.5 billion in market capitalization, Alexion has grown to become a major player in the biotech world, yet its current valuation does not give credit to the potential and pipeline of its overall business. And it seems Amgen has taken notice. Although there’s some pressure on Amgen to do a deal given the Bristol Myers’ recent acquisition of Celgene, the Alexion deal is attractive nonetheless...